Equasens Stock
Equasens Stock price
Key metrics
Is Equasens a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 7,032 stocks worldwide.
Equasens Stock Analysis
Analyst Opinions
6 Analysts have issued a Equasens forecast:
Analyst Opinions
6 Analysts have issued a Equasens forecast:
Financial data from Equasens
| Dec '24 |
+/-
%
|
||
| Revenue | 217 217 |
1%
1%
|
|
| Gross Profit | 149 149 |
1%
1%
|
|
| EBITDA | 59 59 |
15%
15%
|
EBIT (Operating Income) EBIT | 44 44 |
21%
21%
|
| Net Profit | 36 36 |
23%
23%
|
|
In millions EUR.
Don't miss a Thing! We will send you all news about Equasens directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Equasens engages in the development of management software packages for drugstores. The company is headquartered in Villers-Les-Nancy, Grand Est. The company went IPO on 2000-10-20. The firm is engaged in publishing and integration of software packages intended for pharmacies, hospitals, health establishments, laboratories, retirement homes and health professionals. Its activity is distributed in publishing and integration of software packages for pharmacies, publishing of IT solutions for health and medico-social establishments and development of solutions and infrastructure for e-Health. The company provides software packages for managing databases, information, stocks, orders, electronic care sheets, etc. The company offers publishing and integration of software packages for retirement homes, hospitals and care homes (software for managing admissions, invoicing, tracking collections and accounting, care monitoring, stewardship management, etc. );
| Head office | France |
| Employees | 1,271 |
| Website | equasens.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
